Latest Insider Transactions at Zenas Bio Pharma, Inc. (ZBIO)
This section provides a real-time view of insider transactions for Zenas Bio Pharma, Inc. (ZBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zenas BioPharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zenas BioPharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 04
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
45,000
+15.73%
|
$405,000
$9.98 P/Share
|
|
Dec 03
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+11.3%
|
$250,000
$10.76 P/Share
|
|
Nov 19
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+1.44%
|
$35,000
$14.57 P/Share
|
|
Nov 18
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,500
+4.26%
|
$112,500
$15.0 P/Share
|
|
Sep 20
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.15%
|
$90,000
$18.42 P/Share
|
|
Sep 19
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.3%
|
$85,000
$17.89 P/Share
|
|
Sep 18
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.6%
|
$170,000
$17.91 P/Share
|
|
Sep 16
2024
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
801,624
+37.06%
|
-
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
882,353
+19.0%
|
$15,000,001
$17.0 P/Share
|
|
Sep 16
2024
|
Enavate Sciences Gp, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,879,006
+50.0%
|
-
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Open market or private purchase
|
Indirect |
882,352
+23.46%
|
$14,999,984
$17.0 P/Share
|
|
Sep 16
2024
|
Jason Raleigh Nunn |
BUY
Conversion of derivative security
|
Indirect |
2,174,449
+50.0%
|
-
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Open market or private purchase
|
Indirect |
440,000
+36.23%
|
$7,480,000
$17.0 P/Share
|
|
Sep 16
2024
|
Patrick G Enright Director |
BUY
Conversion of derivative security
|
Indirect |
2,061,934
+45.58%
|
-
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Open market or private purchase
|
Indirect |
2,235,294
+29.7%
|
$37,999,998
$17.0 P/Share
|
|
Sep 16
2024
|
Sr One Capital Management, LLC |
BUY
Conversion of derivative security
|
Indirect |
2,676,245
+50.0%
|
-
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
300,000
+15.75%
|
$5,100,000
$17.0 P/Share
|
|
Sep 16
2024
|
Fairmount Funds Management LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,304,891
+39.1%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
156,635
+36.78%
|
-
|
|
Sep 16
2024
|
Leon O Moulder Jr Chief Executive Officer |
BUY
Conversion of derivative security
|
Indirect |
536,540
+45.47%
|
-
|
|
Sep 13
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
58,823
+50.0%
|
$999,991
$17.0 P/Share
|